Oncology

Latest News

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

May 6th 2025

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com
COA 2025: Insight, Innovation, and Independent Strength

May 5th 2025

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com
Patient Navigation Is Nonnegotiable in Cancer Care

May 1st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Dr Roger Brito Discusses Implementing Alternative Payment Models and Its Challenges
January 20th 2018

Dr Roger Brito Discusses Implementing Alternative Payment Models and Its Challenges

Aetna is focusing on the healthcare triangle (patients, providers, and payers) and connecting those lines, said Roger Brito, DO, national director for oncology, Aetna.
This Week in Managed Care: January 19, 2018
January 19th 2018

This Week in Managed Care: January 19, 2018

This week in managed care, the top stories included the announcement that Kentucky is the first state approved to require patients work to receive Medicaid benefits; FDA Commissioner Scott Gottlieb, MD, reveals a new program to improve clinical trial transparency; research finds the worst cases of attention-deficit/hyperactivity disorder could lower life expectancy.
Risk-Targeted Lung Cancer Screening Shows Modest Benefits
January 19th 2018

Risk-Targeted Lung Cancer Screening Shows Modest Benefits

Samantha DiGrande
Although risk targeting may improve screening efficiency in terms of early lung cancer mortality per person screened, the gains in efficiency are modest in terms of life-years, quality-adjusted life-years, and cost-effectiveness, according to a study recently published in Annals of Internal Medicine.
Terrill Jordan Discusses the Process of Customizing an EMR to Adapt to OCM
January 19th 2018

Terrill Jordan Discusses the Process of Customizing an EMR to Adapt to OCM

In order to adapt to the Oncology Care Model (OCM), Regional Cancer Care Associates had to undergo the process of adjusting and customizing its electronic medical records, explained CEO Terrill Jordan.
Horizon, RCCA Launch Pilot to Close Care Gaps Between Cancer Treatments
January 19th 2018

Horizon, RCCA Launch Pilot to Close Care Gaps Between Cancer Treatments

Mary Caffrey
New Jersey's largest payer will track a host of measures, including some that will evaluate the quality of end-of-life care.
Dr Mark Fendrick: Setting Cost-Sharing Based on Value, Not Price, in Cancer Care
January 18th 2018

Dr Mark Fendrick: Setting Cost-Sharing Based on Value, Not Price, in Cancer Care

We should try to remove barriers that are not only in place, but getting higher for clinicians and patients to get evidence-based care, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.
Site Logo
January 18th 2018

Electronic Health Record Problem Lists: Accurate Enough for Risk Adjustment?

Timothy J. Daskivich, MD, MSHPM Garen Abedi, MD, MS Sherrie H. Kaplan, PhD, MPH Douglas Skarecky, BS Thomas Ahlering, MD Brennan Spiegel, MD, MSHS Mark S. Litwin, MD, MPH Sheldon Greenfield, MD
Electronic health record (EHR)-based comorbidity assessment had low sensitivity for identifying major comorbidities and poorly predicted survival. EHR-based comorbidity data require validation prior to application to risk adjustment.
Study Finds Protein Markers May Better Predict Drug Response in Patients With AML Than Genetic Mutations
January 18th 2018

Study Finds Protein Markers May Better Predict Drug Response in Patients With AML Than Genetic Mutations

AJMC Staff
A study finds that protein markers may be a better predictor of drug response than genetic mutation are in patients with acute myeloid leukemia (AML). As a result, some patients who could benefit from treatment may not be eligible under current approval specifications.
Poor Baseline LIPI Associated With Worse Outcomes for ICI Treatment in Patients With NSCLC
January 16th 2018

Poor Baseline LIPI Associated With Worse Outcomes for ICI Treatment in Patients With NSCLC

Jaime Rosenberg
Poor baseline Lung Immune Prognistic Index (combining derived neutrophils ratio greater than 3 and lactate dehydrogenase greater than upper limit of normal), or LIPI, was associated with worse outcomes for immune checkpoint inhibitor (ICI) treatment in patients with non-small cell lung cancer (NSCLC), but not with results of chemotherapy, according to a study in JAMA Oncology.
What We're Reading: Language of Medicine; Uninsured Number Grows; 3D Mammograms
January 16th 2018

What We're Reading: Language of Medicine; Uninsured Number Grows; 3D Mammograms

AJMC Staff
The language used by doctors contributes to why patients don't understand what they are told; the number of American adults without health insurance grew 1.3 percentage points from the end of 2016 to the end of 2017; women are increasingly faced with the decision between 2D and 3D mammograms.
Julie Wolfson: Supporting AYAs Before and After Treatment
January 14th 2018

Julie Wolfson: Supporting AYAs Before and After Treatment

The challenges that adolescents and young adults face before and after treatment are all unique to an individual patient, according to Julie Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.
FDA Approves Olaparib for Breast Cancer With a BRCA Gene Mutation
January 13th 2018

FDA Approves Olaparib for Breast Cancer With a BRCA Gene Mutation

Jaime Rosenberg
The approval expands the use of olaparib to include the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer. The FDA also expanded the approval of Myriad’s BRCAnalysis CDx, a companion diagnostic to olaparib, to include the detection of BRCA mutations.
Dr Jeff Patton Discusses Preparing for OCM, Seeing Improved Outcomes and Savings
January 12th 2018

Dr Jeff Patton Discusses Preparing for OCM, Seeing Improved Outcomes and Savings

It’s very unusual to see significant cost savings in the first year of a program; that was true of all the pioneer ACO programs, said Jeff Patton, MD, CEO of Tennessee Oncology.
Over Half of Octogenarians, Nonagenarians With NSCLC Do Not Receive Treatment
January 12th 2018

Over Half of Octogenarians, Nonagenarians With NSCLC Do Not Receive Treatment

Jaime Rosenberg
More than half of octogenarians and nonagenarians with stage III non–small-cell lung cancer did not receive treatment, according to a study in CANCER. Older age, black race, and living in a lower educated census tract were found to be risk factors for not receiving treatment.
Dr Peter Aran on Involving Providers in Development Process of New Reimbursement Models
January 11th 2018

Dr Peter Aran on Involving Providers in Development Process of New Reimbursement Models

Involving providers in the development process of new reimbursement models increases the chance that the initiative will be successful and works against caregiver burnout, said Peter Aran, MD, medical director of Population Health Management at Blue Cross Blue Shield of Oklahoma.
AstraZeneca's Osimertinib on Track for First-Line Treatment of NSCLC With a Specific Mutation
January 11th 2018

AstraZeneca's Osimertinib on Track for First-Line Treatment of NSCLC With a Specific Mutation

Allison Inserro
AstraZeneca’s epidermal growth factor receptor (EGFR) inhibitor, osimertinib (Tagrisso), is on the fast track in 2018 to become a first-line treatment for adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations.
Lenvatinib, Pembrolizumab Combination Therapy for Patients With RCC Granted Breakthrough Therapy Designation
January 11th 2018

Lenvatinib, Pembrolizumab Combination Therapy for Patients With RCC Granted Breakthrough Therapy Designation

Jaime Rosenberg
Eisai’s multiple receptor tyrosine kinase inhibitor lenvatinib and Merck’s anti–PD-1 therapy pembrolizumab as a combination therapy for patients with renal cell carcinoma received the designation based on results from the renal cell carcinoma cohort in Study 111.
Sarah Cevallos on Her Advice for Practices Looking to Participate in OCM
January 10th 2018

Sarah Cevallos on Her Advice for Practices Looking to Participate in OCM

Don’t underestimate the power that it takes to make sure a value-based program is working, said Sarah Cevallos, chief revenue cycle officer, Florida Cancer Specialists.
Site Logo
January 9th 2018

US Cancer Mortality Rates Continue to Drop, According to New Report

Jaime Rosenberg
A report from the American Cancer Society estimated new cancer cases and deaths for 2018 and took a look at the most recent data to determine cancer incidence through 2014 and mortality through 2015.
Dr Roger Brito: What Patients Should Know About Alternative Payment Models, OCM
January 9th 2018

Dr Roger Brito: What Patients Should Know About Alternative Payment Models, OCM

The healthcare triangle (patients, payers, and providers) begins with the patient, so we should include the patient in some of the decision-making, said Roger Brito, DO, national director for oncology, Aetna.
FDA Approves Denosumab for Prevention of Skeletal-Related Events in Patients with Multiple Myeloma
January 9th 2018

FDA Approves Denosumab for Prevention of Skeletal-Related Events in Patients with Multiple Myeloma

Jaime Rosenberg
The approval will expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to also include patients with multiple myeloma.
Combination Therapy May Benefit Subset of Patients With CLL Who Have Poor Response to Ibrutinib
January 7th 2018

Combination Therapy May Benefit Subset of Patients With CLL Who Have Poor Response to Ibrutinib

AJMC Staff
A subset of patients with chronic lymphocytic leukemia (CLL) with highly expressed CD49d have poorer outcomes while on Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B-cell receptor (BCR) signals. However, a team of researchers may have found a way to treat these patients.
Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care
January 7th 2018

Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care

The fact that you have certain drugs that treat numerous cancers, and that they may treat 1 cancer different or better than another, would suggest that we should probably have differential pricing models, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.
Study Examines Cost-Effectiveness in Multiple Myeloma Treatments
January 6th 2018

Study Examines Cost-Effectiveness in Multiple Myeloma Treatments

Kaitlynn Ely
New drugs to treat multiple myeloma (MM) have provided clinical benefits, but a study published in the Journal of Managed Care & Specialty Pharmacy found not all of them can be considered cost effective.
Study Examines Cost-Effectiveness in Multiple Myeloma Treatments
January 6th 2018

Study Examines Cost-Effectiveness in Multiple Myeloma Treatments

Kaitlynn Ely
New drugs to treat multiple myeloma (MM) have provided clinical benefits, but a study published in the Journal of Managed Care & Specialty Pharmacy found not all of them can be considered cost effective.
Patients With Small-Cell Lung Cancer Face Barriers to Combined-Modality Therapy
January 5th 2018

Patients With Small-Cell Lung Cancer Face Barriers to Combined-Modality Therapy

Jaime Rosenberg
While chemotherapy with thoracic radiation has been established as the standard of care for the initial treatment of non-metastatic small-cell lung cancer, a large proportion of patients do not receive these treatments and in turn have lower overall survival, according to a study published in JAMA Oncology.
AJMC® in the Press, January 5, 2018
January 5th 2018

AJMC® in the Press, January 5, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Bo Gamble on COA's Role in 2018
January 5th 2018

Bo Gamble on COA's Role in 2018

Bo Gamble, director of Strategic Practice Initiatives at the Community Oncology Alliance (COA), believes that broadening communication and education is COA’s main goal in 2018.
Judy Berger on What Southwest Airlines Is Doing in Oncology
January 4th 2018

Judy Berger on What Southwest Airlines Is Doing in Oncology

Southwest Airlines has set up a split fill program, pharmacy benefit manager, health advocacy program, and a cancer resource guide for employees, said Judy Berger, senior manager, benefits planning, Southwest Airlines.
Judge Dismisses Challenge to 340B Cuts, Final Rule Goes Into Effect
January 4th 2018

Judge Dismisses Challenge to 340B Cuts, Final Rule Goes Into Effect

Jaime Rosenberg
A federal judge dismissed a move to block 340B cuts days before CMS’ final rule on it went into effect.
<1
...
575859606162636465
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo